financetom
Business
financetom
/
Business
/
Pembina Pipeline Ratings, Price Targets, Reiterated at RBC Capital Markets and National Bank After Q4 Results
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Pembina Pipeline Ratings, Price Targets, Reiterated at RBC Capital Markets and National Bank After Q4 Results
Feb 28, 2025 8:34 AM

11:07 AM EST, 02/28/2025 (MT Newswires) -- RBC Capital Markets and National Bank of Canada on Friday maintained their ratings and price targets on the shares of Pembina Pipeline ( PBA ) following fourth-quarter results from the oil and gas processing and infrastructure comapny.

RBC reiterated its outperform rating and $65.00 price target on the share of the company after it reported "solid" results in the quarter, including EBITDA of $1.25 billion that beat RBC's forecast of $1.13 billion and the consensus estimate of $1.13 billion.

RBC noted that Pembina also reiterated its 2025 EBITDA guidance range of $4.2 billion to 4.5 billion, which is expected have a slightly positive impact on the company's share price.

National Bank of Canada kept Pembina shares rated at sector perform rating with a $58.00 price target..

Pembina's adjusted EBITDA of $1.25 billion also beat the bank's forecast of $1.12 billion, reflecting stronger performance across the pipelines and facilities segments as well as higher NGL marketing contributions, National Bank said.

Price: 55.62, Change: +3.11, Percent Change: +5.92

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Axogen Smashes 52-Week High On FDA Nod For Breakthrough Nerve Repair Treatment
Axogen Smashes 52-Week High On FDA Nod For Breakthrough Nerve Repair Treatment
Mar 10, 2026
The U.S. Food and Drug Administration (FDA) on Wednesday approved Axogen Inc.’s Biologics License Application for Avance, an acellular nerve scaffold for adult and pediatric patients aged 1 month or older with sensory, mixed, and motor peripheral nerve discontinuities. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated...
AMD chief says company ready to pay 15% tax on AI chip shipments to China
AMD chief says company ready to pay 15% tax on AI chip shipments to China
Mar 10, 2026
SAN FRANCISCO, Dec 4 (Reuters) - Advanced Micro Devices ( AMD ) CEO Lisa Su on Thursday said the company has licenses to ship some of its MI 308 chips to China and is prepared to pay a 15% tax to the U.S. government if it ships them. Su made the remarks at a conference held by technology publication Wired...
AMD chief says company ready to pay 15% tax on AI chip shipments to China
AMD chief says company ready to pay 15% tax on AI chip shipments to China
Mar 10, 2026
SAN FRANCISCO, Dec 4 (Reuters) - Advanced Micro Devices ( AMD ) CEO Lisa Su on Thursday said the company has licenses to ship some of its MI 308 chips to China and is prepared to pay a 15% tax to the U.S. government if it ships them. Su made the remarks at a conference held by technology publication Wired...
Belden Insider Sold Shares Worth $306,480, According to a Recent SEC Filing
Belden Insider Sold Shares Worth $306,480, According to a Recent SEC Filing
Mar 10, 2026
01:22 PM EST, 12/04/2025 (MT Newswires) -- Leah Tate, Senior Vice President, Human Resources, on December 03, 2025, sold 2,554 shares in Belden (BDC) for $306,480. Following the Form 4 filing with the SEC, Tate has control over a total of 27,835 common shares of the company, with 27,835 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/913142/000119312525307844/xslF345X05/ownership.xml Price: 120.46, Change: +0.36, Percent...
Copyright 2023-2026 - www.financetom.com All Rights Reserved